These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9990069)

  • 1. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.
    Lode HN; Moehler T; Xiang R; Jonczyk A; Gillies SD; Cheresh DA; Reisfeld RA
    Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1591-6. PubMed ID: 9990069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
    Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
    Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
    Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma.
    Ruehlmann JM; Xiang R; Niethammer AG; Ba Y; Pertl U; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Dec; 61(23):8498-503. PubMed ID: 11731434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
    Mitjans F; Meyer T; Fittschen C; Goodman S; Jonczyk A; Marshall JF; Reyes G; Piulats J
    Int J Cancer; 2000 Sep; 87(5):716-23. PubMed ID: 10925366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.
    Trikha M; Zhou Z; Nemeth JA; Chen Q; Sharp C; Emmell E; Giles-Komar J; Nakada MT
    Int J Cancer; 2004 Jun; 110(3):326-35. PubMed ID: 15095296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.
    Lode HN; Xiang R; Dreier T; Varki NM; Gillies SD; Reisfeld RA
    Blood; 1998 Mar; 91(5):1706-15. PubMed ID: 9473237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.
    Becker JC; Varki N; Gillies SD; Furukawa K; Reisfeld RA
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7826-31. PubMed ID: 8755561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells.
    Dkhissi F; Lu H; Soria C; Opolon P; Griscelli F; Liu H; Khattar P; Mishal Z; Perricaudet M; Li H
    Hum Gene Ther; 2003 Jul; 14(10):997-1008. PubMed ID: 12869217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
    Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
    Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
    Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
    Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.
    Burrows FJ; Thorpe PE
    Proc Natl Acad Sci U S A; 1993 Oct; 90(19):8996-9000. PubMed ID: 7692443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.
    Lode HN; Xiang R; Duncan SR; Theofilopoulos AN; Gillies SD; Reisfeld RA
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8591-6. PubMed ID: 10411920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What to do with targeted IL-2.
    Lode HN; Xiang R; Perri P; Pertl U; Lode A; Gillies SD; Reisfeld RA
    Drugs Today (Barc); 2000 May; 36(5):321-36. PubMed ID: 12861355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
    Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
    Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice.
    Dabrowska-Iwanicka A; Olszewska D; Jalili A; Makowski M; Grzela T; Marczak M; Hoser G; Giermasz A; Golab J; Jakóbisiak M
    J Cancer Res Clin Oncol; 2002 Aug; 128(8):433-42. PubMed ID: 12200600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.